KTTA: מכפיל P/S Pasithea Therapeutics

The venture potential of Pasithea Therapeutics (KTTA) is based on small molecule patents, as confirmed by the daily chart from the GURU.Markets service. The price-to-sales ratio, where the value 39.40 indicates the current figure, correlates with significant pricing power in the neurobiology segment. Strict FDA regulations and the high cost of clinical trials serve as business protections, creating a substantial barrier to entry for new players.

Maximum outsourcing of synthesis and testing at Pasithea Therapeutics (KTTA) minimizes capital expenditures by shifting operational risk to external contractors. The market capitalization-to-revenue ratio, represented by the fundamental P/S, allows investors to decouple price volatility from static sales, determining the premium paid for a business model with a lean management structure.